📰
Politics
AbbVie's Deal with Apogee; Regenxbio Moves on Gene Therapy Drug | Stock Movers
📅22 June 2026 at 15:08
📰Bloomberg
👁️0 views
Share:
✅
Full Article Content Loaded
Complete article with 640 characters of detailed content
Full Article•Reading time: ~2 min•100 words
ℹ️
Chrome Audio Reader: This audio reader has been optimized for Chrome's speech synthesis. If you experience issues, try using Edge or Firefox as they have more reliable speech synthesis.
Chrome Known Issues: Chrome sometimes has voice loading delays. The system will automatically retry with simplified settings if needed. For best results, try Edge or Firefox browsers.
🔇
Audio Reader
Not supported in this browser
On this episode of Stock Movers with Nathan Hager:
- Apogee (APGE) shares are soaring on news AbbVie is closing in on a nearly $11 billion deal to buy inflammatory disease drug developer Apogee Therapeutics. That's also according to a Financial Times report.
- Regenxbio (RGNX) shares are moving on news Regenxbio aligned with the FDA on next steps for a potential accelerated approval of Navsunli, a gene therapy for Mucopolysaccharidosis II, with the FDA confirming the company doesn’t need to conduct additional studies of the drug.
- SpaceX (SPCX) is lower this morning, continuing its slide after its record IPO. (Source: Bloomberg)
Article Details
📰Source: Bloomberg
⚡Content fetched on-demand for optimal performance
✨Enhanced with BBC-inspired formatting
Reading Statistics
640
Characters
100
Words
Share this story
Share:
Source: This article was originally published by Bloomberg. All rights reserved to the original publisher.
Comments
Loading comments...
Related Stories
Stay Updated
Get the latest Nigerian news delivered to your inbox.